Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2

Authors

Levent Mutlu, Department of Obstetrics, Gynecology, and Reproductive Sciences, 333 Cedar Street, LSOG 305, PO Box 208063, New Haven, CT, 06520, USA.Follow
Blair McNamara, Department of Obstetrics, Gynecology, and Reproductive Sciences, 333 Cedar Street, LSOG 305, PO Box 208063, New Haven, CT, 06520, USA.
Stefania Bellone, Department of Obstetrics, Gynecology and Reproductive Sciences, Yale School of Medicine, New Haven, CT.Follow
Diego D. Manavella, Department of Obstetrics, Gynecology, and Reproductive Sciences, 333 Cedar Street, LSOG 305, PO Box 208063, New Haven, CT, 06520, USA.
Cem Demirkiran, Department of Obstetrics, Gynecology, and Reproductive Sciences, 333 Cedar Street, LSOG 305, PO Box 208063, New Haven, CT, 06520, USA.
Michelle Greenman, Department of Obstetrics, Gynecology, and Reproductive Sciences, 333 Cedar Street, LSOG 305, PO Box 208063, New Haven, CT, 06520, USA.
Migues Skyler Z. Veroza, Department of Obstetrics, Gynecology, and Reproductive Sciences, 333 Cedar Street, LSOG 305, PO Box 208063, New Haven, CT, 06520, USA.
Natalia Buza, Department of Pathology, Yale University School of Medicine, New Haven, Connecticut.Follow
Pei Hui, Smilow Comprehensive Cancer Center, Yale School of Medicine, New Haven, CT, USA.Follow
Tobias Max Philipp Harwitch, Department of Obstetrics, Gynecology, and Reproductive Sciences, 333 Cedar Street, LSOG 305, PO Box 208063, New Haven, CT, 06520, USA.
Justin Harold, Smilow Comprehensive Cancer Center, Yale School of Medicine, New Haven, CT, USA.Follow
Margherita Zipponi, Department of Obstetrics, Gynecology, and Reproductive Sciences, 333 Cedar Street, LSOG 305, PO Box 208063, New Haven, CT, 06520, USA.
Gary Altwerger, Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale School of Medicine, New Haven, CT, 06510, USA.Follow
Elena Ratner, Department of Obstetrics, Gynecology, and Reproductive Sciences, 333 Cedar Street, LSOG 305, PO Box 208063, New Haven, CT, 06520, USA.Follow
Gloria S. Huang, Smilow Comprehensive Cancer Center, Yale School of Medicine, New Haven, CT, USA.Follow
Mitchell Clark, Department of Obstetrics/Gynecology, Yale New Haven Health, Bridgeport Hospital, Bridgeport, CT.Follow
Vaagn Andikyan, Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, Yale School of Medicine, New Haven, CT, USA.Follow
M Azodi, Yale University, New Haven, Connecticut.Follow
Peter E. Schwartz, Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06520, USA.Follow
Alessandro D. Santin, Department of Obstetrics, Gynecology and Reproductive Sciences, Yale School of Medicine, New Haven, CT.Follow

Document Type

Article

Publication Title

Clinical and Experimental Metastasis

First Page

765

Last Page

778

DOI

10.1007/s10585-024-10297-z

Publication Date

10-2025

Recommended Citation

Mutlu L, McNamara B, Bellone S, Manavella DD, Demirkiran C, Greenman M, Verzosa MSZ, Buza N, Hui P, Hartwich TMP, Harold J, Yang-Hartwich Y, Zipponi M, Altwerger G, Ratner E, Huang GS, Clark M, Andikyan V, Azodi M, Schwartz PE, Santin AD. Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2. Clin Exp Metastasis. 2024 Oct;41(5):765-775. doi: 10.1007/s10585-024-10297-z.

Source Document Type

English

e-ISSN

1573-7276